Total loss of MHC class I is an independent indicator of good prognosis in breast cancer

Madjd, Zahra; Spendlove, Ian; Pinder, Sarah; Ellis, Ian O.; Durrant, Lindy G.

doi:10.1002/ijc.21163

Cited by 132 publications

(119 citation statements)

References 33 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…The loss of surface antigens, such as major histocompatibility (MHC) class I, is an independent indicator of good prognosis in breast cancer. 106 It has also been well-documented that cancer patients' sera contain an impressive variety of immunosuppressive proteins, indicating that many immunosuppressive substances may be secreted from either tumor or host cells.107 These substances, secreted in the tumor microenvironment, can be defined as part of the tumor secretome. Results from our current proteomics analysis provide a molecular explanation for the properties of ECM in breast cancer cells.…”

Section: Discussionmentioning

confidence: 99%

Breast Tumor Microenvironment: Proteomics Highlights the Treatments Targeting Secretome

et al. 2008

View full text Add to dashboard Cite

Tumor secreted substances (secretome), including extracellular matrix (ECM) components, act as mediators of tumor-host communication in the breast tumor microenvironment. Proteomic analysis has emphasized the value of the secretome as a source of prospective markers and drug targets for the treatment of breast cancers. Utilizing bioinformatics, our recent studies revealed global changes in protein expression after the activation of ECM-mediated signaling in breast cancer cells. A newly designed technique integrating a capillary ultrafiltration (CUF) probe with mass spectrometry was demonstrated to dynamically sample and identify in vivo and pure secretome from the tumor microenvironment. Such in vivo profiling of breast cancer secretomes may facilitate the development of novel drugs specifically targeting secretome.

show abstract

Section: Discussionmentioning

confidence: 99%

Breast Tumor Microenvironment: Proteomics Highlights the Treatments Targeting Secretome

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Basically, normal cells express MHC class I molecules, whereas aberrant cells such as cancer cells extinguish the expression of MHC class I molecules on themselves [55] . This phenomenon was especially observed in pancreatic [56] , cervical [57] , breast [58] , prostatic [59] , and penile cancer PBMCs from each time point were extracted and co-cultured with monoclonal antibodies against CD3 and CD28 to measure IFN-g and IL-2 production levels in each supernatant. Results are shown as fold over the control (Pre) for the average of five separate donors, and expressed as mean ± SEM.…”

Section: Hyperthermia Enhances Immune Systems In Response To Cancermentioning

confidence: 98%

Cancer immunity and therapy using hyperthermia with immunotherapy, radiotherapy, chemotherapy, and surgery

Yagawa¹,

Tanigawa²,

Kobayashi³

et al. 2017

JCMT

View full text Add to dashboard Cite

Hyperthermia is a type of medical modality for cancer treatment using the biological effect of artificially induced heat. Even though the intrinsic effects of elevated body temperature in cancer tissues are poorly understood, increasing the temperature of the body has been recognized as a popular therapeutic method for tumorous lesions as well as infectious diseases since ancient times. Recently accumulated evidence has shown that hyperthermia amplifies immune responses in the body against cancer while decreasing the immune suppression and immune escape of cancer. It also shows that hyperthermia inhibits the repair of damaged cancer cells after chemotherapy or radiotherapy. These perceptions indicate that hyperthermia has potential for cancer therapy in conjunction with immunotherapy, chemotherapy, radiotherapy, and surgery. Paradoxically, the anticancer effect of hyperthermia alone has not yet been adequately exploited because deep heating techniques and devices to aggregate heat effects only in cancer tissues are difficult in practical terms. This review article focuses on the current understanding concerning cancer immunity and involvement of hyperthermia and the innate and adoptive immune system. The potential for combination therapy with hyperthermia and chemotherapy, radiotherapy, and surgery is also discussed. Key words:Hyperthermia, cancer immunity, chemosensitizer, radiosensitizer, combination cancer therapy, hyperthermic intraoperative peritoneal chemotherapy ABSTRACTArticle history:

show abstract

“…By contrast, other reports have revealed that MHC class I loss may improve patients' survival through activating natural killer (NK) cell function (7,8). These results vary between different types of tumors and the occurrence of lymph node metastasis (5,7).…”

Section: Introductionmentioning

confidence: 96%

“…Certain studies have reported that MHC class I loss has poor outcomes due to its impact on antigen presentation to T-lymphocytes and CTLs (5,6). By contrast, other reports have revealed that MHC class I loss may improve patients' survival through activating natural killer (NK) cell function (7,8). These results vary between different types of tumors and the occurrence of lymph node metastasis (5,7).…”

Section: Introductionmentioning

confidence: 99%

NLRC5 expression in tumors and its role as a negative prognostic indicator in stage III non-small-cell lung cancer patients

Guo

Liu

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. Major histocompatibility complex (MHC) class I molecules have a crucial role in tumor immune evasion; however, the association of MHC class I molecules with outcomes in cancer patients remains controversial. Nucleotide-binding oligomerization-like receptor family caspase recruitment domain-containing 5 (NLRC5) has been reported to be a MHC class I transactivator. However, the expression and function of NLRC5 in cancer remains to be elucidated. The present study aimed to retrospectively examine NLRC5 expression in human tumor tissues and its association with clinical outcomes of non-small-cell lung cancer (NSCLC) stage III patients. The expression of MHC class I and NLRC5 in NSCLC were detected using immunohistochemistry (IHC). The association between their expression levels was assessed using the Pearson's χ 2 test and their association with survival was assessed using Kaplan-Meier analysis and the log-rank test. In addition, the expression of NLRC5 and MHC class I were examined in 323 cases of seven other types of tumors and their correlations were studied. The results revealed that the expression of NLRC5 was correlated with that of MHC class I in NSCLC patients (P=0.008). MHC class I-positive and nuclear NLRC5-positive NSCLC patients were found to have shorter overall survival (OS) rates (log-rank, P=0.032 and P=0.039, respectively). In addition, in the seven different tumor types, there was a significant correlation between MHC class I and NLRC5 nuclear expression (P<0.001) as well as MHC class I and NLRC5 cytoplasmic expression (P=0.003). In conclusion, NLRC5 was demonstrated to be widely expressed in eight tumor tissues and its expression was correlated with that of MHC class I. Of note, nuclear NLRC5-negative and MHC class I-negative stage III NSCLC patients had improved OS rates compared to those with positive expression. Therefore, NLRC5 and MHC class I may be negative prognostic indicators in NSCLC stage III patients.

show abstract

Total loss of MHC class I is an independent indicator of good prognosis in breast cancer

Cited by 132 publications

References 33 publications

Breast Tumor Microenvironment: Proteomics Highlights the Treatments Targeting Secretome

Breast Tumor Microenvironment: Proteomics Highlights the Treatments Targeting Secretome

Cancer immunity and therapy using hyperthermia with immunotherapy, radiotherapy, chemotherapy, and surgery

NLRC5 expression in tumors and its role as a negative prognostic indicator in stage III non-small-cell lung cancer patients

Contact Info

Product

Resources

About